Atomic resolution crystal structures of HIV‐1 protease and mutants V82A and I84V with saquinavir

Saquinavir (SQV), the first antiviral HIV‐1 protease (PR) inhibitor approved for AIDS therapy, has been studied in complexes with PR and the variants PRI84V and PRV82A containing the single mutations I84V and V82A that provide resistance to all the clinical inhibitors. Atomic resolution crystal structures (0.97–1.25 Å) of the SQV complexes were analyzed in comparison to the protease complexes with darunavir, a new drug that targets resistant HIV, in order to understand the molecular basis of drug resistance. PRI84V and PRV82A complexes were obtained in both the space groups P21212 and P212121, which provided experimental limits for the conformational flexibility. The SQV interactions with PR were very similar in the mutant complexes, consistent with the similar inhibition constants. The mutation from bigger to smaller amino acids allows more space to accommodate the large group at P1′ of SQV, unlike the reduced interactions observed in darunavir complexes. The residues 79–82 have adjusted to accommodate the large hydrophobic groups of SQV, suggesting that these residues are intrinsically flexible and their conformation depends more on the nature of the inhibitor than on the mutations in this region. This analysis will assist with development of more effective antiviral inhibitors. Proteins 2007. © 2007 Wiley‐Liss, Inc.

[1]  Rational approaches to resistance: using saquinavir. , 1996, AIDS.

[2]  Z. Otwinowski,et al.  [20] Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.

[3]  M Karplus,et al.  Relation between sequence and structure of HIV-1 protease inhibitor complexes: a model system for the analysis of protein flexibility. , 2002, Journal of molecular biology.

[4]  J S Mills,et al.  Antiviral properties of Ro 31-8959, an inhibitor of human immunodeficiency virus (HIV) proteinase. , 1991, Antiviral research.

[5]  A Wlodawer,et al.  Inhibitors of HIV-1 protease: a major success of structure-assisted drug design. , 1998, Annual review of biophysics and biomolecular structure.

[6]  C. Debouck,et al.  Structural role of the 30's loop in determining the ligand specificity of the human immunodeficiency virus protease. , 1998, Biochemistry.

[7]  Irene T Weber,et al.  Mechanism of drug resistance revealed by the crystal structure of the unliganded HIV-1 protease with F53L mutation. , 2006, Journal of molecular biology.

[8]  Ursula Rothlisberger,et al.  Drug resistance in HIV‐1 protease: Flexibility‐assisted mechanism of compensatory mutations , 2002, Protein science : a publication of the Protein Society.

[9]  J. Louis,et al.  Influence of flanking sequences on the dimer stability of human immunodeficiency virus type 1 protease. , 1996, Biochemistry.

[10]  A. Velázquez‐Campoy,et al.  HIV-1 protease inhibitors: enthalpic versus entropic optimization of the binding affinity. , 2000, Biochemistry.

[11]  M. Hatada,et al.  Novel binding mode of highly potent HIV-proteinase inhibitors incorporating the (R)-hydroxyethylamine isostere. , 1991, Journal of medicinal chemistry.

[12]  R M Esnouf,et al.  Further additions to MolScript version 1.4, including reading and contouring of electron-density maps. , 1999, Acta crystallographica. Section D, Biological crystallography.

[13]  J. Louis,et al.  Chemical synthesis and expression of the HIV-1 protease gene in E. coli. , 1989, Biochemical and biophysical research communications.

[14]  Arun K. Ghosh,et al.  Effectiveness of nonpeptide clinical inhibitor TMC-114 on HIV-1 protease with highly drug resistant mutations D30N, I50V, and L90M. , 2006, Journal of medicinal chemistry.

[15]  J. Louis,et al.  Flap opening and dimer-interface flexibility in the free and inhibitor-bound HIV protease, and their implications for function. , 1999, Structure.

[16]  I. Weber,et al.  Development of a microtiter plate fluorescent assay for inhibition studies on the HTLV-1 and HIV-1 proteinases. , 2004, Journal of virological methods.

[17]  Irene T. Weber,et al.  Novel bis-Tetrahydrofuranylurethane-Containing Nonpeptidic Protease Inhibitor (PI) UIC-94017 (TMC114) with Potent Activity against Multi-PI-Resistant Human Immunodeficiency Virus In Vitro , 2003, Antimicrobial Agents and Chemotherapy.

[18]  P. Kissinger,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. , 1998, The New England journal of medicine.

[19]  M. Ott,et al.  In vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: mutations, kinetics, and frequencies. , 1996, The Journal of infectious diseases.

[20]  S. Gulnik,et al.  Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure. , 1995, Biochemistry.

[21]  L. Bacheler,et al.  Resistance to HIV protease inhibitors: a comparison of enzyme inhibition and antiviral potency. , 1998, Biochemistry.

[22]  J. Zou,et al.  Improved methods for building protein models in electron density maps and the location of errors in these models. , 1991, Acta crystallographica. Section A, Foundations of crystallography.

[23]  L Hong,et al.  Crystal structure of an in vivo HIV‐1 protease mutant in complex with saquinavir: Insights into the mechanisms of drug resistance , 2000, Protein science : a publication of the Protein Society.

[24]  Irene T Weber,et al.  Kinetic, stability, and structural changes in high-resolution crystal structures of HIV-1 protease with drug-resistant mutations L24I, I50V, and G73S. , 2005, Journal of molecular biology.

[25]  T. Chou,et al.  Evaluation of reverse transcriptase and protease inhibitors in two-drug combinations against human immunodeficiency virus replication , 1996, Antimicrobial agents and chemotherapy.

[26]  Michele Parrinello,et al.  Role of conformational fluctuations in the enzymatic reaction of HIV-1 protease. , 2002, Journal of molecular biology.

[27]  A. Wlodawer,et al.  Structure-based inhibitors of HIV-1 protease. , 1993, Annual review of biochemistry.

[28]  H. B. Schock,et al.  An alternate binding site for the P1-P3 group of a class of potent HIV-1 protease inhibitors as a result of concerted structural change in the 80s loop of the protease. , 2000, Acta crystallographica. Section D, Biological crystallography.

[29]  Irene T Weber,et al.  High resolution crystal structures of HIV-1 protease with a potent non-peptide inhibitor (UIC-94017) active against multi-drug-resistant clinical strains. , 2004, Journal of molecular biology.

[30]  J. Navaza,et al.  AMoRe: an automated package for molecular replacement , 1994 .

[31]  H. B. Schock,et al.  Non-active Site Changes Elicit Broad-based Cross-resistance of the HIV-1 Protease to Inhibitors* , 1999, The Journal of Biological Chemistry.

[32]  G. Satten,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.

[33]  Irene T Weber,et al.  Crystal structures of HIV protease V82A and L90M mutants reveal changes in the indinavir-binding site. , 2004, European journal of biochemistry.

[34]  C. Schiffer,et al.  Viability of a Drug-Resistant Human Immunodeficiency Virus Type 1 Protease Variant: Structural Insights for Better Antiviral Therapy , 2003, Journal of Virology.

[35]  Celia A. Schiffer,et al.  Structural and Thermodynamic Basis for the Binding of TMC114, a Next-Generation Human Immunodeficiency Virus Type 1 Protease Inhibitor , 2004, Journal of Virology.

[36]  Irene T Weber,et al.  Ultra-high resolution crystal structure of HIV-1 protease mutant reveals two binding sites for clinical inhibitor TMC114. , 2006, Journal of molecular biology.

[37]  R M Stroud,et al.  Domain flexibility in retroviral proteases: structural implications for drug resistant mutations. , 1998, Biochemistry.

[38]  G. Sheldrick,et al.  SHELXL: high-resolution refinement. , 1997, Methods in enzymology.

[39]  P. Massip,et al.  Prevalence of drug resistant mutants and virological response to combination therapy in patients with primary HIV‐1 infection , 2000, Journal of medical virology.

[40]  J. Tözsér,et al.  Proteolytic events of HIV-1 replication as targets for therapeutic intervention. , 2003, Current pharmaceutical design.

[41]  J. Condra,et al.  In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors , 1995, Nature.

[42]  Irene T Weber,et al.  Molecular basis for substrate recognition and drug resistance from 1.1 to 1.6 Å resolution crystal structures of HIV‐1 protease mutants with substrate analogs , 2005, The FEBS journal.

[43]  I B Duncan,et al.  Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959. , 1995, Virology.